Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Vaccines01:21

Vaccines

Vaccines are among the most effective tools in preventive medicine, designed to prepare the immune system to recognize and combat infectious agents. By introducing antigens—substances that the immune system identifies as foreign—vaccines stimulate an adaptive immune response that leads to immunological memory. This immunological memory enables the body to mount a faster and more effective response upon future exposures to the actual pathogen.Vaccines can be categorized based on the type of...
Retrovirus Life Cycles01:10

Retrovirus Life Cycles

Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the retrovirus to...
Vaccinations01:51

Vaccinations

Overview
Inhibitors of Virion Maturation and Assembly01:19

Inhibitors of Virion Maturation and Assembly

As part of their replication cycle, certain viruses synthesize long precursor proteins called polyproteins within infected host cells. In human immunodeficiency virus (HIV), two major polyproteins are produced: Gag and Gag-Pol. The Gag polyprotein supplies the structural components of the virus, while Gag-Pol includes essential viral enzymes such as reverse transcriptase, integrase, and protease. After synthesis, these polyproteins move to the host cell membrane, where they assemble into an...
Poliomyelitis01:17

Poliomyelitis

Poliomyelitis is caused by poliovirus, a small, non-enveloped, positive-sense RNA virus of the Picornaviridae family and Enterovirus genus. Transmission occurs primarily via the fecal-oral route, often through ingestion of contaminated water or food. The virus initially replicates in the oropharynx and intestinal mucosa, particularly in lymphoid tissues such as the tonsils, Peyer’s patches, and regional lymph nodes. Primary viremia follows, allowing dissemination throughout the body.In most...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

ISV Congress back to Europe.

Human vaccines & immunotherapeutics·2018
Same author

Improved simulation-optimization approach for identifying critical and developable pollution source regions and critical migration processes for pollutant load allocation.

The Science of the total environment·2018
Same author

DNA Vaccination in 2018: An Update.

Human gene therapy·2018
Same author

Mup-knockout mice generated through CRISPR/Cas9-mediated deletion for use in urinary protein analysis.

Acta biochimica et biophysica Sinica·2018
Same author

Select gp120 V2 domain specific antibodies derived from HIV and SIV infection and vaccination inhibit gp120 binding to α4β7.

PLoS pathogens·2018
Same author

Nuclear Receptor SHP: A Critical Regulator of miRNA and lncRNA Expression and Function.

Nuclear receptor research·2018
Same journal

Human Papillomavirus (HPV)-The Interplay between Vaginal Microbiota and HPV, along with its Prevention.

Current HIV research·2026
Same journal

Metabolic Syndrome Prevalence Among People Living With HIV: A Single-Center Study From Türkiye.

Current HIV research·2026
Same journal

Weight Change with Long-Acting Cabotegravir Plus Rilpivirine in People with HIV: Targeted Review and Meta-Analysis.

Current HIV research·2026
Same journal

Corrigendum to: Impact of HIV-1 Tat on FDFT1 Suppression, Changes in Cholesterol Level, and KSHV Replication in BCBL1 Cells.

Current HIV research·2026
Same journal

Study of Class I HDAC-1, -2, and -3 Inhibitors Designed by Bioisosteric Replacement of Zinc Binding Groups and Caps of Traditional Pan Inhibitors: An <i>In Silico</i> Approach.

Current HIV research·2026
Same journal

Sociodemographic and Clinical Characteristics of Individuals Receiving Post-Exposure Prophylaxis (PEP) for HIV in the Republic of Cyprus: A Cross-sectional Study.

Current HIV research·2026
See all related articles

Related Experiment Video

Updated: Jun 7, 2026

Utilizing the Antigen Capsid-Incorporation Strategy for the Development of Adenovirus Serotype 5-Vectored Vaccine Approaches
13:36

Utilizing the Antigen Capsid-Incorporation Strategy for the Development of Adenovirus Serotype 5-Vectored Vaccine Approaches

Published on: May 6, 2015

Polyvalent AIDS vaccines.

Shan Lu1, Jill M Grimes Serrano, Shixia Wang

  • 1Laboratory of Nucleic Acid Vaccines, Department of Medicine, University of Massachusetts Medical School, Worcester, MA 01605, USA. shan.lu@umassmed.edu

Current HIV Research
|November 9, 2010
PubMed
Summary
This summary is machine-generated.

Developing a polyvalent HIV-1 vaccine, which targets multiple viral variants, is a promising strategy to overcome viral diversity. This approach addresses limitations of previous vaccine designs and offers a viable path toward an effective HIV vaccine.

More Related Videos

Conformational Evaluation of HIV-1 Trimeric Envelope Glycoproteins Using a Cell-based ELISA Assay
07:10

Conformational Evaluation of HIV-1 Trimeric Envelope Glycoproteins Using a Cell-based ELISA Assay

Published on: September 14, 2014

Production of E. coli-expressed Self-Assembling Protein Nanoparticles for Vaccines Requiring Trimeric Epitope Presentation
10:58

Production of E. coli-expressed Self-Assembling Protein Nanoparticles for Vaccines Requiring Trimeric Epitope Presentation

Published on: August 21, 2019

Related Experiment Videos

Last Updated: Jun 7, 2026

Utilizing the Antigen Capsid-Incorporation Strategy for the Development of Adenovirus Serotype 5-Vectored Vaccine Approaches
13:36

Utilizing the Antigen Capsid-Incorporation Strategy for the Development of Adenovirus Serotype 5-Vectored Vaccine Approaches

Published on: May 6, 2015

Conformational Evaluation of HIV-1 Trimeric Envelope Glycoproteins Using a Cell-based ELISA Assay
07:10

Conformational Evaluation of HIV-1 Trimeric Envelope Glycoproteins Using a Cell-based ELISA Assay

Published on: September 14, 2014

Production of E. coli-expressed Self-Assembling Protein Nanoparticles for Vaccines Requiring Trimeric Epitope Presentation
10:58

Production of E. coli-expressed Self-Assembling Protein Nanoparticles for Vaccines Requiring Trimeric Epitope Presentation

Published on: August 21, 2019

Area of Science:

  • Immunology
  • Vaccinology
  • Virology

Background:

  • HIV-1 vaccine development faces challenges due to significant viral diversity.
  • Previous vaccine strategies focused on either T cell or antibody responses, rarely both, with limited success.
  • Failures of trials like STEP and VaxGen highlighted the need for broader antigen coverage.

Purpose of the Study:

  • To review existing HIV-1 vaccination approaches based on the polyvalent principle.
  • To provide a historical perspective on polyvalent vaccine development for HIV-1.
  • To assess the viability of the polyvalent approach for future HIV vaccine design.

Main Methods:

  • Literature review of HIV-1 vaccination strategies.
  • Analysis of historical vaccine trial data (STEP, VaxGen).
  • Evaluation of polyvalent vaccine successes in other pathogens.

Main Results:

  • Past HIV vaccine efforts were limited by narrow antigen focus.
  • Polyvalent approaches have proven successful against other diverse pathogens.
  • Review indicates the polyvalent strategy is a viable direction for HIV-1 vaccine development.

Conclusions:

  • The polyvalent vaccine approach is a promising strategy to address HIV-1 diversity.
  • This approach overcomes limitations of previous single-target vaccine designs.
  • Further development of polyvalent HIV-1 vaccines is recommended for future efficacy.